TCRR - TCR2 Therapeutics GAAP EPS of -$0.79 beats by $0.06
- TCR2 Therapeutics press release ( NASDAQ: TCRR ): Q3 GAAP EPS of -$0.79 beats by $0.06 .
- TCR 2 ended the third quarter of 2022 with $176.0 million in cash, cash equivalents, and investments compared to $265.6 million as of December 31, 2021.
For further details see:
TCR2 Therapeutics GAAP EPS of -$0.79 beats by $0.06